Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 625,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Boxer Capital Management, Llc sold 625,000 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $7.05, for a total transaction of $4,406,250.00. Following the sale, the insider now owns 7,573,642 shares of the company’s stock, valued at $53,394,176.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tango Therapeutics Trading Down 5.6 %

Shares of TNGX stock opened at $6.27 on Thursday. The company has a market capitalization of $669.92 million, a P/E ratio of -5.55 and a beta of 0.81. The business’s 50 day moving average is $8.85 and its two-hundred day moving average is $8.49. Tango Therapeutics, Inc. has a twelve month low of $6.12 and a twelve month high of $13.01.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. The firm had revenue of $19.88 million for the quarter, compared to analyst estimates of $7.39 million. Tango Therapeutics had a negative net margin of 274.04% and a negative return on equity of 44.73%. As a group, equities analysts predict that Tango Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Tango Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Artal Group S.A. purchased a new stake in Tango Therapeutics in the 1st quarter valued at approximately $17,427,000. Point72 Asset Management L.P. purchased a new stake in shares of Tango Therapeutics in the second quarter valued at approximately $3,836,000. Vanguard Group Inc. grew its holdings in Tango Therapeutics by 3.4% during the first quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock worth $24,462,000 after acquiring an additional 101,673 shares during the period. Dimensional Fund Advisors LP raised its position in Tango Therapeutics by 42.5% in the second quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock worth $2,882,000 after acquiring an additional 100,257 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Tango Therapeutics by 110.8% in the fourth quarter. Wellington Management Group LLP now owns 170,228 shares of the company’s stock valued at $1,685,000 after acquiring an additional 89,481 shares during the period. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on TNGX shares. Wedbush lifted their price target on shares of Tango Therapeutics from $11.00 to $13.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Jefferies Financial Group assumed coverage on Tango Therapeutics in a research report on Wednesday, July 17th. They set a “buy” rating and a $19.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Tuesday, September 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a research note on Tuesday, July 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.